L Porres - Genomma Lab Legal Officer
Insider
L Porres is Legal Officer of Genomma Lab Internacional
| Phone | 52 55 5081 0000 |
| Web | https://www.genommalab.com |
Genomma Lab Management Efficiency
The company has return on total asset (ROA) of 0.0921 % which means that it generated a profit of $0.0921 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1264 %, meaning that it generated $0.1264 on every $100 dollars invested by stockholders. Genomma Lab's management efficiency ratios could be used to measure how well Genomma Lab manages its routine affairs as well as how well it operates its assets and liabilities.Genomma Lab Internacional has accumulated 3.83 B in total debt with debt to equity ratio (D/E) of 0.51, which is about average as compared to similar companies. Genomma Lab Internacional has a current ratio of 1.64, which is within standard range for the sector. Debt can assist Genomma Lab until it has trouble settling it off, either with new capital or with free cash flow. So, Genomma Lab's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Genomma Lab Internacional sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Genomma to invest in growth at high rates of return. When we think about Genomma Lab's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Hlio Segouras | Hypera SA | N/A | |
| Ken Gelhaus | Alpha Teknova | 40 | |
| Robert Ronn | Orexo AB | 47 | |
| Robert Weinstein | Petros Pharmaceuticals | 64 | |
| Albert Bolles | Lifecore Biomedical | 67 | |
| Brian Grow | Organogenesis Holdings | 49 | |
| Sonny Newman | C21 Investments | N/A | |
| David Francisco | Organogenesis Holdings | 59 | |
| Damon Terrill | Alpha Teknova | 53 | |
| Luiz Clavis | Hypera SA | N/A | |
| Eric Shoemaker | C21 Investments | N/A | |
| Juliana Salem | Hypera SA | N/A | |
| Aaron Perlitsh | Lifecore Biomedical | N/A | |
| Mitchell MBA | Petros Pharmaceuticals | 61 | |
| Adam Mostafa | Cumberland Pharmaceuticals | 45 | |
| MD MBA | Orexo AB | N/A | |
| BA Esq | Organogenesis Holdings | 55 | |
| Dennis Urbaniak | Orexo AB | 54 | |
| Cecilia Coupland | Orexo AB | 47 | |
| Keith Lavan | Petros Pharmaceuticals | 60 | |
| Kurt Matheson | Organogenesis Holdings | N/A | |
Management Performance
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0921 |
Genomma Lab Internacional Leadership Team
Elected by the shareholders, the Genomma Lab's board of directors comprises two types of representatives: Genomma Lab inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genomma. The board's role is to monitor Genomma Lab's management team and ensure that shareholders' interests are well served. Genomma Lab's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genomma Lab's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Efran Crdova, Deputy Sec | ||
| Engineer Galland, Exec CFO | ||
| Marianne Velasco, Global HR | ||
| Mximo Juda, Advisor | ||
| L Porres, Legal Officer | ||
| Daniel Neria, Head Relations | ||
| Jorge Valderrama, Chief Officer | ||
| Juan Sparvieri, Ex COO | ||
| Alejandro Patio, Media, Relations |
Genomma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Genomma Lab a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0921 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 1.09 B | |||
| Shares Outstanding | 1 B | |||
| Shares Owned By Insiders | 29.00 % | |||
| Shares Owned By Institutions | 29.10 % | |||
| Price To Earning | 11.09 X | |||
| Price To Book | 1.38 X |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Genomma Pink Sheet
If you are still planning to invest in Genomma Lab Internacional check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Genomma Lab's history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |